Latest news with #AcuteLymphoblasticLeukemia
Yahoo
20-05-2025
- Health
- Yahoo
Metro Atlanta 4-year-old finishes cancer battle that took more than half his life
After spending more than half of his life battling cancer, a 4-year-old metro Atlanta boy has finished his treatment. Austin Herre rang the bell at Children's Arthur M. Blank Hospital this week after 854 days of treatment. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] His mother said he was diagnosed with Adrenoleukodystrophy (ALD) at just six months old more than two years ago. ALD is a rare disease that affects 1 in 17,000 people. It's a neurological disorder that affects the adrenal glands and brain and causes long-chain fatty acids in the brain, which destroy the protective myelin sheath around nerve cells responsible for brain function. In January 2023, he was also diagnosed with Acute Lymphoblastic Leukemia. TRENDING STORIES: This metro Atlanta city is ranked No. 1 on new 'Best Places to Live in the U.S.' list Keisha Lance Bottoms makes it official, announces run for Georgia governor Parents sue after they say 6-year-old daughter was racially attacked at school: 'It's disturbing' That same year, he was able to visit a Cherokee County fire station to see some fire trucks and was named an honorary firefighter. Members of the Cherokee County Fire Department reunited with him to be at the ceremony marking the end of his treatment. [SIGN UP: WSB-TV Daily Headlines Newsletter]
Yahoo
13-05-2025
- Health
- Yahoo
Lee's Summit West student passes away after battle with Leukemia
LEE'S SUMMIT, Mo. — Lee's Summit West High School is mourning the loss of Keaton Miller, a junior student and wrestler at the high school. Miller, 17, passed away after a year-long battle with Leukemia. on April 25 at Journey Church International in Lee's Summit. New 52,000 square foot sports facility in Lee's Summit set to open Miller had undergone a bone marrow transplant earlier this year and was recovering but recently had to be admitted to intensive care. Other Lee's Summit West sports teams held several fundraising events over the past year for Miller and Acute Lymphoblastic Leukemia research. Principal Kayla Maid confirmed his death in a letter sent to families, adding that grief counselors will be at the school this week. 'Titan Families, It is with a heavy heart that I share the news that Keaton Miller, a junior at Lee's Summit West High School, passed away this afternoon after a courageous year-long battle with B-cell Acute Lymphoblastic Leukemia. Keaton was a beloved member of our Titan family. He was a proud member of our wrestling program, a dedicated student, and a young man whose infectious personality left a lasting impact on all who knew him. Even during his treatment, Keaton remained connected to his classmates and teachers, showing strength, optimism, and unwavering love for the Titan community. This is an incredibly difficult loss, and we recognize the deep emotional impact this may have on our students, staff, and families. Tomorrow, we will have additional counselors and mental health support available at school for anyone who may need someone to talk to or process this news with care and compassion. If you are concerned about your student and would like one of our staff members to check in on them, please complete this form. Additionally, this district resource provides helpful information on supporting individuals through grief. You may find it useful as you navigate this difficult time with your student. If you have any questions or believe your student would benefit from additional support, please do not hesitate to reach out. With care, Kayla MaidPrincipal, Lee's Summit West High School' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
09-04-2025
- Health
- Yahoo
Lackawanna County residents rally for 20-year-old cancer patient
THROOP, LACKAWANNA COUNTY (WBRE/WYOU) — A local college student is in the fight of his life, battling cancer. Lackawanna County residents are rallying around him as the 20-year-old is now in search of a blood stem cell donor. All week long, there are swab events to help find a bone marrow match for Eddie Kaufman. The 20-year-old Mid Valley alumnus has been battling leukemia since the fall. 28/22 News spoke with his dad and friends earlier Tuesday about Eddie's diagnosis and the race to find him a match. 'I would like to be the one to help him out, potentially save his life… we've been best friends since preschool,' Eddie's friend Jaden Carroll explained. Carroll, a Sophomore at Penn State Scranton, says he's hopeful he is a bone marrow match for his lifelong friend Eddie Kaufman. 'It was shocking, I mean it just goes to show that it could happen to anybody because I thought that was the healthiest, most athletic kid I knew,' Carroll explained. After starting his second year at Roanoke College last fall, the standout baseball player was diagnosed with T-Cell Acute Lymphoblastic Leukemia. Cold case arrest after body found in garbage bags on I-80 'He had gone back to school in Virginia. He called and said he's got some swollen lymph nodes and something's going on, and that was the first sign there was an issue,' Eddie's father, Brian Kaufman, said. The diagnosis is a form of cancer that impacts blood, tissue, and bone marrow. Months into the fight, Eddie is now in search of a blood stem cell donor. 'They warned us going in that 70% of family members are not perfect matches, and we fell into that 70%,' Brian continued. Family and friends are now pushing to find the Mid-Valley alum a perfect donor match. 'Everybody just kind of came together and decided that we should find this match for Eddie,' said Eddie's Friend Emily Deoliveira. Contractor sued for alleged 'subpar' work, violations Through the National Marrow Donor Program, the community is holding several swab events across Lackawanna County. Anyone ages 18 to 40 can be a potential donor; all it takes is a simple cheek swab. For potential future matches, 90% of donations are non-surgical and are as simple as giving plasma. 'There's a lot of people out there that need a bone marrow transplant, and 22,000,000 people are in the database. It sounds like a lot, but it's not enough,' Brian added. 'We're getting a lot of love for Eddie, which is really, really nice,' Deoliveira said. Team Eddie K is growing locally and beyond. The swab results take about one to two weeks to come back. There are also campaigns going on in Virginia, Georgia, and New York. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Fox News
05-04-2025
- Sport
- Fox News
Dean Wells, former NFL linebacker and Kentucky standout, dead at 54 following cancer battle
Dean Wells, who played for nearly a decade in the NFL following a standout career at the University of Kentucky, died Thursday following a two-year battle with cancer. He was 54. Wells spent the first six years of his NFL career with the Seattle Seahawks after he was selected in the fourth round of the 1993 draft. He signed with the Carolina Panthers in 1999, where he played for another three seasons before officially retiring in 2001. The Panthers announced Wells' passing on the team website Friday. Wells first opened up about his cancer diagnosis in an interview with in April 2024. He said he had been diagnosed the previous year with Acute Lymphoblastic Leukemia (ALL). "There's mental toughness that comes into it. You have to have a positive attitude that you can beat it. I've done everything that I can with that. It's like the chemo either works or it doesn't. You just don't have a lot of control over it. You wish you had more control," he said at the time. According to the Mayo Clinic, Acute Lymphoblastic Leukemia is a cancer of the blood and bone marrow in which "the disease progresses rapidly and creates immature blood cells, rather than mature ones." Wells finished his pro career with 529 tackles, 2.5 sacks, six forced fumbles, four fumble recoveries, and three interceptions. It followed a standout career at Kentucky where Wells still holds the records for most sacks in a game (5) and the single-season sack record (10). "Condolences to family & friends of Dean Wells, who has passed away," the university said in a statement on social media. "A 3-year starter, he set a UK single-game record with 5 sacks vs. Indiana and went on to a 9-year NFL career. After NFL retirement, he returned to hometown Louisville and was a staunch supporter of the Wildcats." Wells is survived by his wife, Lisa, and their two sons. Follow Fox News Digital's sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.
Globe and Mail
03-04-2025
- Business
- Globe and Mail
T-Cell Acute Lymphoblastic Leukemia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'T-Cell Acute Lymphoblastic Leukemia Pipeline Insight 2025' report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the T-Cell Acute Lymphoblastic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the T-Cell Acute Lymphoblastic Leukemia Treatment Landscape. Click here to read more @ T-Cell Acute Lymphoblastic Leukemia Pipeline Outlook Key Takeaways from the T-Cell Acute Lymphoblastic Leukemia Pipeline Report In March 2025, Janssen Research & Development LLC announced a study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate. In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL). In March 2025, Beam Therapeutics Inc. announced a phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to < 12 years), and a Phase 2 cohort. In March 2025, Wugen Inc. conducted a study is to evaluate the Composite Complete Remission Rate (CRc) of WU-CART-007 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) patients and to evaluate the efficacy of WU-CART-007 to induce complete Minimum Residual Disease (MRD) negative response. DelveInsight's T-Cell Acute Lymphoblastic Leukemia pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for T-Cell Acute Lymphoblastic Leukemia treatment. The leading T-Cell Acute Lymphoblastic Leukemia Companies such as Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others. Promising T-Cell Acute Lymphoblastic Leukemia Therapies such as WU-CART-007, LY3039478, Dexamethasone, Vincristine, Daunorubicin, and others. Stay informed about the cutting-edge advancements in T-Cell Acute Lymphoblastic Leukemia treatments. Download for updates and be a part of the revolution in cancer care @ T-Cell Acute Lymphoblastic Leukemia Clinical Trials Assessment T-Cell Acute Lymphoblastic Leukemia Emerging Drugs Profile AST-3424: Ascentawits Pharmaceuticals AST-3424 is a first-in-class small molecule coupled targeted drug developed by the Aixindawei R&D team that relies on AKR1C3 enzyme activation. It selectively cleaves the aldehyde-keto reductase family 1 member C3 (AKR1C3) into a cytotoxic active form (AST-2660). The diaziridine (AST-2660) released by AST-3424 is similar to the standard chemotherapy drugs thiotepa and mitomycin C, which alkylates and cross-links DNA at the N7 (or O6) position of guanine, leading to cell death. SWOG was commissioned by the National Cancer Institute (NCI) to conduct a Phase II clinical study of relapsed and refractory T-ALL. The Phase II clinical study of relapsed and refractory T-ALL is a single-arm, open-label, OBI-3424 monotherapy (one treatment cycle every 21 days, with administration on the 1st and 8th days) led by SWOG (Southwest Oncology Group) with the National Cancer Institute as the main sponsor. The commercial rights for AST-3424 outside of Asia belong to the company's global partner OBI. Currently, the drug is in Phase II stage of its development for the treatment of T-ALL. WU-CART-007: Wugen WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global Phase I/II clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). WU-CART-007 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration for the treatment of R/R T-ALL/LBL. Learn more about T-Cell Acute Lymphoblastic Leukemia Drugs opportunities in our groundbreaking Melanoma research and development projects @ T-Cell Acute Lymphoblastic Leukemia Unmet Needs T-Cell Acute Lymphoblastic Leukemia Companies Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others. T-Cell Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. T-Cell Acute Lymphoblastic Leukemia Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in T-Cell Acute Lymphoblastic Leukemia treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ T-Cell Acute Lymphoblastic Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the T-Cell Acute Lymphoblastic Leukemia Pipeline Report Coverage- Global T-Cell Acute Lymphoblastic Leukemia Companies- Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others. T-Cell Acute Lymphoblastic Leukemia Therapies- WU-CART-007, LY3039478, Dexamethasone, Vincristine, Daunorubicin, and others. T-Cell Acute Lymphoblastic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination T-Cell Acute Lymphoblastic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of T-Cell Acute Lymphoblastic Leukemia Pipeline on our website @ T-Cell Acute Lymphoblastic Leukemia Emerging Drugs and Companies Table of Content Introduction Executive Summary T-Cell Acute Lymphoblastic Leukemia: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) AST-3424: Ascentawits Pharmaceuticals Drug profiles in the detailed report….. Early stage products (Phase I) WU-CART-007: Wugen Drug profiles in the detailed report….. Inactive Products T-Cell Acute Lymphoblastic Leukemia Key Companies T-Cell Acute Lymphoblastic Leukemia Key Products T-Cell Acute Lymphoblastic Leukemia- Unmet Needs T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion T-Cell Acute Lymphoblastic Leukemia Analyst Views T-Cell Acute Lymphoblastic Leukemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
